Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2.
Baris Turkbey, Andrew B Rosenkrantz, Masoom A Haider...
https://pubmed.ncbi.nlm.nih.gov/30898406/Actively Recruiting
Led by The University of Hong Kong · Updated on 2026-08-26
60
Participants Needed
1
Research Sites
14 weeks
Total Duration
This research investigates the use of pelvis-only 18F-PSMA-1007 PET-CT imaging to detect clinically significant prostate cancers csPCa that are invisible on standard multiparametric MRI mpMRI. The study focuses on men aged 50 and older with localized, intermediate-risk prostate cancer, particularly those with MRI-invisible cancer areas identified only through biopsy. The goal is to see if PET-CT can guide targeted focal therapy, avoiding whole-gland treatment or active surveillance. This is a prospective, multi-center, single-arm Phase II trial conducted in Hong Kong. Participants undergo a PET-CT scan to detect PET-positive lesions that correspond to MRI-invisible biopsy sites. Those with matching PET-avid lesions receive focal therapy using one of three energy-based treatments targeted microwave ablation, high-intensity focused ultrasound, or irreversible electroporation. Treatments are carefully guided by organ-based tracking technology fused with real-time ultrasound, aiming to cover the PET-positive lesions plus any MRI-visible tumors with safety margins while protecting nearby critical structures. Treatments are delivered transperineally under anesthesia. During the study, participants have follow-ups at 3 and 6 months including PSA blood tests, symptom and quality-of-life questionnaires, and repeat imaging and biopsies to assess the presence of cancer in treated areas. The main measure is the absence of significant prostate cancer in treated zones at 6 months. Secondary outcomes include cancer recurrence outside treated areas, changes in PSA, functional effects, safety events, and quality of life. The study plans to enroll about 60 patients to achieve 45 treated cases, with a total duration of about 3 years.
CONDITIONS
¹⁸F-PSMA-1007 PET-CT-Directed Focal Therapy for MRI-Invisible Prostate Cancer
S
Shung Lai John Leung, MBBS, FRCSEd, FCSHK, FHKAM
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
The University of Hong Kong
Lead Sponsor
Queen Mary Hospital, Hong Kong
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - Up to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Within 4 weeks after enrollment
Participants undergo a pelvis-only 18F-PSMA-1007 PET-CT scan to detect prostate cancer lesions not visible on MRI.
1 visit (in-person)
Duration - Single treatment session
Participants with PET-positive lesions corresponding to MRI-invisible cancer receive targeted focal therapy using microwave ablation, high-intensity focused ultrasound, or irreversible electroporation under image guidance.
1 treatment visit under anesthesia
Duration - 6 months post-treatment
Participants have follow-up visits at 3 and 6 months including PSA testing, symptom questionnaires, repeat MRI, and biopsy to assess cancer status and side effects.
2 visits (at 3 and 6 months post-treatment)
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Baris Turkbey, Andrew B Rosenkrantz, Masoom A Haider...
https://pubmed.ncbi.nlm.nih.gov/30898406/Veeru Kasivisvanathan, Antti S Rannikko, Marcelo Borghi...
https://pubmed.ncbi.nlm.nih.gov/29552975/Daniel Dindo, Nicolas Demartines, Pierre-Alain Clavien
https://pubmed.ncbi.nlm.nih.gov/15273542/Jeffrey J Tosoian, Mufaddal Mamawala, Jonathan I Epstein...
https://pubmed.ncbi.nlm.nih.gov/31918957/Taimur T Shah, Max Peters, David Eldred-Evans...
https://pubmed.ncbi.nlm.nih.gov/30638633/Nicolas Barry Delongchamps, Alexandre Peltier, Eric Potiron...
https://pubmed.ncbi.nlm.nih.gov/41810596/Arvin K George, Ranko Miocinovic, Amit R Patel...
https://pubmed.ncbi.nlm.nih.gov/40685282/Hashim U Ahmed, Ahmed El-Shater Bosaily, Louise C Brown...
https://pubmed.ncbi.nlm.nih.gov/28110982/Armando Stabile, Clement Orczyk, Feargus Hosking-Jervis...
https://pubmed.ncbi.nlm.nih.gov/30753756/Willemien van den Bos, Matthijs J Scheltema, Amila R Siriwardana...
https://pubmed.ncbi.nlm.nih.gov/28796935/The University of Hong Kong
Lead Sponsor
Queen Mary Hospital, Hong Kong
Collaborating Sponsor